文献速递泌尿生殖与妇科肿瘤放疗

高危特征子宫内膜癌患者部分长度近距离放疗与全长度阴道近距离放疗同样有效且毒性更低

Partial-Length Treatment With Brachytherapy in Patients With Endometrial Cancer With High-Risk Features Is as Effective as Full-Length Vaginal Brachytherapy but With Reduced Toxicity.
PubMed 文献 · Pract Radiat Oncol · 2023-06-08

本研究纳入2004至2010年间符合美国近距离放疗学会高危特征标准的子宫内膜癌患者240例,比较辅助高剂量率近距离放疗中全长度阴道放疗(121例)与部分长度阴道放疗(119例)的结局。两组阴道复发率均为0%,近端阴道复发率分别为1.4%和0.9%(P=0.54);全长度组全部发生下段阴道/阴道口3级黏膜炎且镇痛药使用增加(P<0.0001),3级狭窄发生率为23%对0%(P<0.0001)。结论认为部分长度阴道近距离放疗在减少局部复发方面与全长度同样有效,且急性和晚期毒性发生率显著更低。

要点

  • 全长度组与部分长度组阴道复发率均为0%,近端阴道复发率1.4%对0.9%(P=0.54)。
  • 全长度组全部发生下段阴道/阴道口3级黏膜炎,部分长度组为0%(P<0.0001)。
  • 全长度组3级下段阴道/阴道口狭窄发生率为23%,部分长度组为0%(P<0.0001)。

核心结论

  • 部分长度阴道近距离放疗在减少局部复发方面与全长度阴道近距离放疗同样有效,且急性和晚期毒性发生率显著更低。
  • 作者提醒放射肿瘤科医生在高危特征子宫内膜癌患者中谨慎使用全长度阴道近距离放疗。

研究设计与样本

  • 经机构审查委员会批准,识别2004至2010年间接受辅助高剂量率近距离放疗且符合美国近距离放疗学会高危特征标准的子宫内膜癌患者。
  • 高剂量率近距离放疗剂量为21Gy分3次照射至全长度或部分长度阴道。
  • 共240例患者接受高剂量率近距离放疗,其中全长度阴道近距离放疗121例,部分长度阴道近距离放疗119例。
  • 急性与晚期毒性分别采用放射治疗肿瘤学组量表和放射治疗肿瘤学组/欧洲癌症研究与治疗组织分级评估。
  • 阴道复发通过体格检查和巴氏涂片评估,统计分析使用SPSS 23版软件。

主要发现

  • 全长度组中位随访9.5年(范围8-11年),部分长度组中位随访8.5年(范围7-10年)。
  • 全长度组阴道复发率为0%,部分长度组为0%;近端阴道复发率分别为1.4%和0.9%(P=0.54)。
  • 全长度组全部患者发生下段阴道/阴道口3级黏膜炎(P<0.0001),且较部分长度组镇痛药使用增加(P<0.0001)。
  • 全长度组23%患者发生下段阴道/阴道口3级狭窄,部分长度组为0%(P<0.0001)。

关键数值与推荐

  • 美国近距离放疗学会建议:对具有乳头状浆液性/透明细胞组织学、3级状态或广泛淋巴血管浸润等高危特征的子宫内膜癌患者,应考虑全长度阴道近距离放疗以减少远端阴道复发。
  • 高剂量率近距离放疗剂量为21Gy分3次。

临床怎么用

  • 作者提醒放射肿瘤科医生在高危特征子宫内膜癌患者中谨慎使用全长度阴道近距离放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Full-length vaginal (FLV) brachytherapy for patients with endometrial cancer and high-risk features should be considered as per the American Brachytherapy Society to reduce distal vaginal recurrence in patients with endometrial cancers with papillary serous/clear cell histologies, grade 3 status, or extensive lymphovascular invasion. We sought to investigate this patient population and report outcomes of treatment with high-dose-rate (HDR) brachytherapy in women treated with FLV brachytherapy versus partial-length vaginal (PLV) brachytherapy. METHODS AND MATERIALS: With institutional review board approval, we identified patients with endometrial cancer meeting American Brachytherapy Society criteria of high-risk features treated with adjuvant HDR between 2004 and 2010. HDR doses were 21Gy in 3 fractions delivered to either the full-length or partial-length vagina. Acute and late toxicities were evaluated using the Radiation Therapy Oncology Group scale and Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer grading, respectfully. Vaginal recurrences were assessed by physical examination and pap smears. Statistical analyses were performed using SPSS version 23 software. RESULTS: Of 240 patients treated with HDR brachytherapy, 121 were treated with FLV brachytherapy, and 119, with PLV brachytherapy. The median follow-up was 9.5 years (range, 8-11 years) for FLV patients and 8.5 years (range, 7-10 years) for PLV patients; 0% of patients had vaginal recurrences, and 1.4% and 0.9% had proximal vaginal recurrences, respectively (P = .54). All patients treated with FLV brachytherapy developed grade 3 mucositis of the lower vagina/introitus (P < .0001) and had increased analgesics use compared with those treated with PLV brachytherapy (P < .0001). In total, 23% of patients treated with FLV brachytherapy developed grade 3 stenosis of the lower vagina/introitus, in contrast to 0% of patients treated with PLV brachytherapy (P < .0001). CONCLUSIONS: PLV brachytherapy is as effective as FLV brachytherapy in reducing local recurrence and causes a significantly lower incidence of acute and late toxicities. The results of this study caution radiation oncologists regarding the careful use of FLV brachytherapy in patients with endometrial cancer and high-risk features.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wernicke AG, Parashar B, Samuel E, et al. Partial-Length Treatment With Brachytherapy in Patients With Endometrial Cancer With High-Risk Features Is as Effective as Full-Length Vaginal Brachytherapy but With Reduced Toxicity. Pract Radiat Oncol. 2023. PMID: 37295725. doi:10.1016/j.prro.2023.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。